Imagine going to the doctor with depression or multiple sclerosis, but instead of relying mainly on questionnaires and subjective assessments, your brain scan gets analyzed by smart software that reads 11 different types of MRI data at once. That's what this project built — a single software tool that combines all those brain imaging signals and uses machine learning to spot patterns invisible to the human eye. It helps doctors make more objective diagnoses, predict how a disease will progress, and choose the right treatment earlier.
Diagnosing neurological and psychiatric disorders like depression, multiple sclerosis, and schizophrenia still relies heavily on subjective clinical assessments. This leads to delayed diagnoses, wrong treatment choices, and poor monitoring — costing healthcare systems and pharma companies enormous time and money. There is no widely available tool that objectively analyzes multiple types of brain MRI data to support these clinical decisions.
A clinical decision support software integrating 11 MRI modalities into a single analysis tool with machine learning classification. The project delivered 4 freeware MRI analysis modules and demonstrated the full system at 2 clinical trial companies, validated on major depression and multiple sclerosis cases.
If you are a medical imaging software company struggling to integrate multiple MRI data types into a single analysis pipeline — this project developed a unified software that combines 11 MRI modalities with machine learning classification, vendor-independent. It was demonstrated at 2 clinical trial companies and produced 4 freeware MRI analysis modules you could build on.
If you are a pharmaceutical company running clinical trials for depression or multiple sclerosis treatments and need objective biomarkers to measure drug effectiveness — this project built a clinical decision support system that quantifies brain changes across 11 MRI modalities. It works independent of vendor-specific scan protocols, making it suitable for multi-site trials across different hospitals.
If you run a neurology or psychiatry department where diagnosis still relies heavily on clinical interviews and subjective scoring — this software provides quantitative, machine-learning-based classification from standard brain MRI scans. It was tested on major depression and multiple sclerosis cases and designed for non-expert users, meaning radiologists and neurologists can use it without specialized data science training.
The project produced 4 freeware MRI analysis modules made available to clinical trial units, suggesting at least parts of the technology are open-access. Commercial licensing terms for the full clinical decision support system would need to be negotiated with the Max Planck Society and consortium partners. Based on available project data, no pricing model was published.
The system was designed to work independent of vendor-specific scan protocols, which is critical for multi-site deployment. It integrates 11 MRI modalities into a single software and was built for non-expert users. It was demonstrated at 2 clinical trial companies, suggesting readiness for multi-site clinical trial environments.
The project was coordinated by Max Planck Society (Germany) with a 7-partner consortium across 4 countries. IP is likely shared according to the consortium agreement. The 4 freeware modules suggest some components are open, while the core clinical decision support system may have separate licensing terms.
Based on available project data, the system was demonstrated in clinical research settings but there is no explicit mention of CE marking or FDA clearance. Clinical decision support software in the EU falls under the Medical Device Regulation (MDR), and regulatory approval would be a necessary step before commercial clinical use.
The project ended in February 2021 and demonstrated the integrated system at clinical trial companies. Moving from research demonstration to routine clinical use typically requires regulatory approval, clinical validation studies, and integration with hospital IT systems. Based on available project data, the technology is past prototype stage but not yet a certified medical product.
The software was specifically designed for interoperability and to work across different MRI vendor protocols. It was built to support large datasets and provide access for non-expert users, suggesting it was designed with clinical workflow integration in mind. Specific PACS or EHR integration details are not available in the project data.
The consortium of 7 partners across 4 countries (Germany, Netherlands, UK, Switzerland) is heavily academic, with 5 universities and 1 research organization led by the Max Planck Society — one of the world's most respected research institutions. There is only 1 industry partner (the single SME), giving a 14% industry ratio. This means the technology is scientifically strong but the commercial translation path will need external business partners. The involvement of clinical trial companies in demonstrations is encouraging, but a commercialization partner or spin-off would likely be needed to bring this to market.
The coordinator is Max Planck Society in Germany. SciTransfer can facilitate an introduction to discuss licensing or partnership opportunities.
Want to explore how this brain MRI analysis technology could fit your clinical trials or diagnostic workflow? Contact SciTransfer for a detailed brief and introduction to the research team.
